Quote this publication Share Print

TREMFYA (guselkumab), interleukin 23 inhibitor immunosuppressant

DERMATOLOGY - New medicinal product
Opinions on drugs - Posted on Dec 18 2018

Reason for request

Inclusion

High clinical benefit for the treatment of severe chronic plaque psoriasis in adults defined by:

  • failure of at least two treatments including non-biological systemic treatments and light therapy

  • and an extensive form and/or significant psychosocial impact

but no demonstrated clinical improvement compared to other anti-interleukins.

Insufficient clinical benefit to justify reimbursement for other forms.

 

  • TREMFYA has MA for the treatment of moderate to severe plaque psoriasis in adults, requiring systemic treatment.

  • It has demonstrated its superiority over HUMIRA (adalimumab).

  • TREMFYA is a second-line systemic treatment to be reserved for adults with severe chronic plaque psoriasis, defined by:

 

  • failure (insufficient response, contraindication or intolerance) of at least two treatments including non-biological systemic treatments and light therapy

  • and an extensive form and/or with significant psychosocial impact.

 


Clinical Benefit

Substantial

-

Insufficient

Clinical Added Value

no clinical added value

-


Therapeutic use

-